Fundraising Fox
/Companies
Sign in

Bright Peak Therapeutics

San Diego, US · Founded 2019 · Delaware corporation · 33 employees on LinkedIn · 9 known investors

Find your way into Bright Peak Therapeutics

215 people in our graph share verified history with the Bright Peak Therapeutics team — schools, employers, funds. One of them is your warm intro.

Beat Schilligunlockedknows Vijaya Pattabiraman · together at Synple Chem (overlapped)
×3knows the team · via Bright Peak Therapeutics
knows the team · via Dr. Reddy's Laboratories
×7knows the team · via University of Alberta

Bright Peak Therapeutics is a biotechnology company developing multi-functional PD-1 inhibitors for cancer immunotherapy, based on its EDC protein-engineering platform. The company operates in the immuno-oncology drug development space.

BiotechHealthtech

Founders & leadership

Bright Peak Therapeutics was founded in 2019 by Vijaya Pattabiraman and Jeffrey Bode.

VPVijaya Pattabiraman
Vijaya PattabiramanCo-founder & Chief Technology OfficerVijaya Pattabiraman is co-founder and CTO of Bright Peak Therapeutics, where he leads discovery and preclinical development programs in immuno-oncology. He has built expertise in protein and small molecule engineering for therapeutic applications through prior academic and translational research.
JBJeffrey Bode
Jeffrey BodeScientific co-founder; Professor at ETH Zürich
FWFredrik Wiklund
Fredrik WiklundChief Executive Officer
CS
Christine SiuNamed on SEC filing
MRMichael Rosenzweig
Michael RosenzweigNamed on SEC filingAdvisor at RA Capital
BK
Bertolt KreftNamed on SEC filing

Board

TWTom Woiwode
Tom WoiwodeBoard directorManaging Director at Versant Ventures
AMAlexander Mayweg
Alexander MaywegBoard MemberManaging Director at Versant Ventures
JRJosh Resnick
Josh ResnickBoard directorPartner at RA Capital

Investors · 9

Johnson & Johnson Innovation – JJDC✓ confirmed by Bright Peak TherapeuticsNew Brunswick

How we know: the company's own site · funding news · Not right? Tell us

Versant Ventures✓ confirmed by Bright Peak TherapeuticsSan Francisco · $250K – $5Mvia Alex Mayweg · board

How we know: the company's own site · a partner's Signal profile · board seat on SEC Form D · funding news · brightpeaktx.com · Not right? Tell us

Venrocklisted by VenrockPalo Alto · $500K – $10M

How we know: funding news · Not right? Tell us

AlexandriareportedPasadena

How we know: brightpeaktx.com · Not right? Tell us

BlackRockreportedMexico City

How we know: brightpeaktx.com · Not right? Tell us

Fidelity InvestmentsreportedBoston

How we know: funding news · brightpeaktx.com · Not right? Tell us

InvusreportedNew York

How we know: funding news · brightpeaktx.com · Not right? Tell us

Qatar Investment AuthorityreportedDoha

How we know: funding news · brightpeaktx.com · Not right? Tell us

Funding

SEC filings, press & company announcements

$196.5M disclosed across 2 of 4 rounds · 2021–2026

▶$90MraisedJun 2024 · 21 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Bertolt KreftExecutive Officer
  • Laura ShawverDirector
  • Tom WoiwodeDirector
  • Vijaya PattabiramanExecutive Officer
  • Matthew RobbinsExecutive Officer
  • Leena GandhiDirector
  • Asish XavierDirector
  • Christine SiuDirector
  • Fredrik WiklundExecutive Officer, Director
  • Emily MinkowDirector
  • Jon WiggintonExecutive Officer
  • Jacob ChackoDirector
Offering amount
$90M
Amount sold
$90M
First sale
May 2024
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$106.5MraisedJun 2021 · 17 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Fredrik WiklundExecutive Officer, Director
  • Christine SiuDirector
  • Michael RosenzweigDirector
  • Bertolt KreftExecutive Officer
  • Tom WoiwodeDirector
  • Alexander MaywegDirector
  • Josh ResnickDirector
Offering amount
$106.5M
Amount sold
$106.5M
First sale
May 2021
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 3

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
bright-mindsBright Minds Biosciences develops selective serotonin receptor agonists (5-HT2A and 5-HT2C) without 5-HT2B activity, built on a proprietary chemistry platform. The company targets central nervous system and brain disorders through serotonin regulation.
ブライトパス・バイオ㈱BrightPath Bio develops novel cancer immunotherapy medicines and cell therapy treatments that enhance the body's natural immune response to eliminate cancer cells. The company builds a platform for developing cell and antibody therapeutics across different cancer types and target antigens, with plans to expand into other immune-modulation therapeutic areas.

Companies working in the same space as Bright Peak Therapeutics.

In the news

Bright Peak Therapeutics Announces $107 Million Series B Financing and Expanded Board of Directors - Bright Peak Therapeuticsbrightpeaktx.com · Jun 2021About - Bright Peak Therapeuticsbrightpeaktx.com · Mar 2021

Frequently asked questions

What does Bright Peak Therapeutics do?
Bright Peak Therapeutics is a biotechnology company developing multi-functional PD-1 inhibitors for cancer immunotherapy, based on its EDC protein-engineering platform. The company operates in the immuno-oncology drug development space.
Who founded Bright Peak Therapeutics?
Bright Peak Therapeutics was founded by Vijaya Pattabiraman, Jeffrey Bode in 2019.
Who are Bright Peak Therapeutics's investors?
Bright Peak Therapeutics's investors include RA Capital, Johnson & Johnson Innovation – JJDC, Versant Ventures, Venrock, Alexandria, BlackRock, Fidelity Investments, Invus and 1 more.
How much funding has Bright Peak Therapeutics raised?
Bright Peak Therapeutics has disclosed $196.5M raised across 2 of its 4 known rounds.
Where is Bright Peak Therapeutics headquartered?
Bright Peak Therapeutics is headquartered in San Diego, US.